Prospective Study of Teclistamab in the Treatment of Systemic AL Amyloidosis
ConditionAL Amyloidosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorPeking University People's Hospital
About this trial
This study aims to evaluate the use of teclistamab in systemic AL amyloidosis and answer whether teclistamab can improve the rate of complete hematological response.
This is a single-arm, multi-center, prospective study. Participants will receive the single drug teclistamab, which the investigator deems the best choice.
Eligibility criteria
Qualifiers
Diagnosis of systemic AL amyloidosis;
Patients must have received standard-of-care daratumumab, bortezomib, they do not have at least one organ response, and have not get complete hematological response;
Life expectancy greater than 12 weeks;
HGB ≥70g/L;
Disqualifiers
Fulfill with the criteria of active multiple myeloma or active lymphoplasmacytic lymphoma.
Presence of other tumors which is/are in advanced malignant stage and has/have systemic metastasis;
Severe or persistent infection that cannot be effectively controlled;
Presence of severe autoimmune diseases or immunodeficiency disease;
Trial design
Treatments tested in this trial
- Teclistamab (Tec)
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Peking University People's Hospital
Lead sponsor
Peking University
Sponsor institution
Source ClinicalTrials.gov